Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15466839 | 0.79 | CA1 (0.37) | CA1CA2 | |
| SCHEMBL8613537 | 0.68 | CA1 (0.39) | CA1CA2 | |
| Indene SCHEMBL1162574 | 0.67 | — | — | |
| SCHEMBL29595470 | 0.67 | — | — | |
| SCHEMBL9178868 | 0.67 | — | — | |
| SCHEMBL8700 | 0.66 | — | — | |
| SCHEMBL29539 | 0.65 | — | — | |
| SCHEMBL5605661 | 0.65 | — | — | |
| SCHEMBL8343541 | 0.63 | TRPA1 (0.34) | TSHRPARP1 | |
| SCHEMBL20528826 | 0.63 | TRPA1 (0.34) | TSHRPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861559-B1 | METHOD AND CATALYST FOR SYNTHESISING AZIRIDINE | UNIV OF EAST ANGLIA (GB) | 2020-09-16 | — | — | EP | disclosed |
| US-10259784-B2 | Method and catalyst for synthesising aziridine | UNIVERSITY OF EAST ANGLIA (GB) | 2019-04-16 | — | — | US | disclosed |
| US-20170342030-A1 | METHOD AND CATALYST FOR SYNTHESISING AZIRIDINE | UNIV OF EAST ANGLIA (GB) | 2017-11-30 | — | — | US | disclosed |
| US-9732034-B2 | Method and catalyst for synthesising aziridine | UNIVERSITY OF EAST ANGLIA (GB) | 2017-08-15 | — | — | US | disclosed |
| US-20170152225-A9 | METHOD AND CATALYST FOR SYNTHESISING AZIRIDINE | UNIVERSITY OF EAST ANGLIA (GB) | 2017-06-01 | — | — | US | disclosed |
| US-20150166478-A1 | METHOD AND CATALYST FOR SYNTHESISING AZIRIDINE | UNIV EAST ANGLIA (GB) | 2015-06-18 | — | — | US | disclosed |
| EP-2861559-A1 | METHOD AND CATALYST FOR SYNTHESISING AZIRIDINE | University of East Anglia (GB) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013179052-A1 | METHOD AND CATALYST FOR SYNTHESISING AZIRIDINE | UNIVERSITY OF EAST ANGLIA (GB) | 2013-12-05 | — | — | WO | disclosed |
| US-20080076700-A1 | Method for the Preparation of Oxime, Thiazolidine, Dithiane, Dithiolane, or Hydrazone Linked Analogues of Growth Hormone | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166478-A1 | METHOD AND CATALYST FOR SYNTHESISING AZIRIDINE | ITPA, PPA1, PPIP5K2 | CA1 1910/4885CA2 814/4885TSHR 1503/4885 |
| US-10259784-B2 | Method and catalyst for synthesising aziridine | ITPA, PPA1, PPIP5K2 | CA1 1833/4885CA2 771/4885TSHR 1511/4885 |
| US-20170342030-A1 | METHOD AND CATALYST FOR SYNTHESISING AZIRIDINE | ITPA, PPA1, PPIP5K2 | CA1 1833/4885CA2 771/4885TSHR 1511/4885 |
| US-20170152225-A9 | METHOD AND CATALYST FOR SYNTHESISING AZIRIDINE | ITPA, PPA1, PPIP5K2 | CA1 1910/4885CA2 814/4885TSHR 1503/4885 |
| US-20080076700-A1 | Method for the Preparation of Oxime, Thiazolidine, Dithiane, Dithiolane, or Hydrazone Linked Analogues of Growth Hormone | THOP1, GHRHR, SHBG | CA1 459/4885CA2 642/4885TSHR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.